Research prototype, not medical advice.

06 — Deregulated nutrient sensing

"Antagonistic" hallmark (López-Otín et al., Cell 2023, doi:10.1016/j.cell.2022.11.001). In plain terms: the sensors that tell the cell "there is food, grow" or "it is a famine, save and repair" stay stuck too long in "growth" mode.

1. Definition

Cells constantly measure the available energy and nutrients through four major networks: IIS (insulin / IGF-1), mTOR (amino acids, growth), AMPK (energy shortage) and sirtuins (NAD+ level). With age, the balance tilts towards the anabolic pathways (high IIS, mTOR) and away from the maintenance pathways (AMPK, sirtuins). Slowing growth and activating maintenance extends life in every model species tested.

2. Mechanisms and sources

GH / insulin / IGF-1 axis (IIS). This is the first longevity pathway discovered: a single mutated gene (daf-2, insulin/IGF receptor) doubles the lifespan of the worm C. elegans (Kenyon 1993, doi:10.1038/366461a0). The effect works through activation of the transcription factor FOXO (DAF-16 in the worm), which switches on stress resistance genes. In humans:

Paradox: during normal aging, GH and IGF-1 fall. This looks like a defensive response of the body, but one that becomes harmful when pushed too far (frailty, sarcopenia).

mTOR. mTOR is a kinase that works in two complexes. mTORC1 senses amino acids (especially leucine), insulin and energy; it stimulates protein and lipid synthesis and slows autophagy (Saxton & Sabatini 2017, doi:10.1016/j.cell.2017.02.004). mTORC2 mainly serves insulin signalling and survival. If mTORC1 stays permanently active in older people, autophagy is blocked, damaged proteins accumulate and the inflammatory secretion of senescent cells is amplified. The data showing this:

AMPK. This is the "low fuel" sensor (high AMP/ATP ratio). It inhibits mTORC1, activates autophagy and the formation of new mitochondria (via PGC-1α). Its capacity to be activated decreases with age. AMPK is the indirect target of metformin and exercise.

Sirtuins. These are NAD+-dependent enzymes that remove acetyl groups from proteins. They link metabolic state to DNA repair, the epigenome and mitochondrial function. In male mice, overexpressing SIRT6 extends life (Kanfi 2012, doi:10.1038/nature10815). As NAD+ falls with age, sirtuins run slowly (see hallmark 07). The promises of resveratrol as a "sirtuin activator" were not confirmed in humans.

Environmental causes. Overeating, excess protein and sugar, a sedentary lifestyle and obesity keep IIS and mTOR in "growth" mode. In the NHANES cohort, a high protein intake between 50 and 65 is associated with higher IGF-1 and more cancers and deaths, with a reversal after 65 (Levine 2014, doi:10.1016/j.cmet.2014.02.006; observational study, so to be interpreted with caution). Diet-longevity synthesis: Fontana & Partridge 2015 (doi:10.1016/j.cell.2015.02.020).

3. Symptoms and clinical manifestations

4. Interactions with the other hallmarks

5. Existing or investigational remedies

InterventionTargetLevel of evidenceKey resultSource
Rapamycin (sirolimus), from 20 months of age in micemTORC1Robust preclinical (ITP, 3 sites)Lifespan +9 % (males) and +14 % (females), even when started lateHarrison 2009, doi:10.1038/nature08221
Transient rapamycin (3 months, middle age)mTORC1PreclinicalUp to +60 % remaining life expectancy, lasting effectBitto 2016, doi:10.7554/eLife.16351
Low-dose everolimus (RAD001), 6 weeksmTORC1Human phase 2 trial (n≈218, ≥65 years)Flu vaccine response increased by about 20 %Mannick 2014, doi:10.1126/scitranslmed.3009892
Low-dose RAD001 + BEZ235mTORC1 (+ PI3K)Human phase 2a trialFewer respiratory infections over one yearMannick 2018, doi:10.1126/scitranslmed.aaq1564
RTB101 (dactolisib)TORC1Human phase 2b then phase 3 trialPositive phase 2b; phase 3 misses its primary endpoint ("clinically symptomatic" respiratory infections)Mannick 2021, doi:10.1016/S2666-7568(21)00062-3
Rapamycin 5-10 mg/week, 48 weeks (PEARL)mTORC1Human phase 2 trial (n=114)Well tolerated; modest signal in women at 10 mg (lean mass, pain); compounded formulation poorly absorbedMoel 2025, doi:10.18632/aging.206235
MetforminAMPK / mitochondrial complex IApproved (diabetes); TAME trial designed but not launched: no registration on ClinicalTrials.gov (search of 19/10/2026), AFAR page offline; several 2026 secondary sources say it is still unfunded [to verify]: no primary sourceDiabetics on metformin: observed mortality similar to or lower than non-diabetics (observational data, possible biases)Bannister 2014, doi:10.1111/dom.12354; Campbell 2017, doi:10.1016/j.arr.2017.08.003; rationale for TAME: Barzilai 2016, doi:10.1016/j.cmet.2016.05.011
Metformin + exercise—Human trial (RCT)Metformin blunts the mitochondrial gains of training in older peopleKonopka 2018, doi:10.1111/acel.12880
Caloric restriction (≈12 % achieved, 2 years, CALERIE)IIS, mTOR, AMPK, sirtuinsHuman phase 2 trial (non-obese)Improved cardiometabolic risk factorsKraus 2019, doi:10.1016/S2213-8587(19)30151-2
CALERIE, biological clocks—Secondary analysis of an RCTSlower pace of aging (DunedinPACE); little effect on GrimAge-type clocksBelsky 2017, doi:10.1093/gerona/glx096; Waziry 2023, doi:10.1038/s43587-022-00357-y
Caloric restriction in primates—Preclinical (rhesus monkeys)Fewer age-related diseases, improved survival; NIA/Wisconsin results reconciledColman 2009, doi:10.1126/science.1173635; Mattison 2017, doi:10.1038/ncomms14063
AcarbosePost-meal glucose spikePreclinical (ITP); approved for diabetesIncreased lifespan, especially in malesHarrison 2014, doi:10.1111/acel.12170
Protein / methionine restrictionmTOR, IGF-1Human observational; preclinicalLower IGF-1, lower mortality between 50 and 65Levine 2014, doi:10.1016/j.cmet.2014.02.006
Genetic inhibition of S6K1mTORC1 → S6K1PreclinicalExtends life (females)Selman 2009, doi:10.1126/science.1177221
SIRT6 overexpressionSirtuinPreclinicalExtends life (males)Kanfi 2012, doi:10.1038/nature10815
Physical exerciseAMPK, insulin sensitivityRecommended (epidemiological evidence and RCTs)Activates AMPK and PGC-1α, restores insulin sensitivityReview: Fontana 2015, doi:10.1016/j.cell.2015.02.020

For the general pharmacological context (rapalogs, selective mTORC1 inhibitors): Bonkowski & Sinclair 2016, doi:10.1038/nrm.2016.93.

6. Open questions

  1. Dose and schedule for rapamycin in humans: is intermittent dosing needed to spare mTORC2? There is still no reliable biomarker of mTORC1 inhibition in tissues. Selective mTORC1 inhibitors remain to be validated clinically.
  2. Metformin: a real anti-aging effect, or an artefact of observational studies ("survival" and comparator biases)? TAME has still not been launched, and metformin hinders adaptation to exercise.
  3. The IGF-1 paradox: does low IGF-1 protect or weaken older people? The effect seems to depend on age, sex and tissue.
  4. Sex differences: many interventions (acarbose, 17α-estradiol, S6K1, SIRT6) act very differently in males and females.
  5. Caloric restriction vs intermittent fasting vs protein composition: what really matters? Long-term adherence remains a major obstacle.
  6. Sirtuins and NAD+: activators (resveratrol, STACs) have not lived up to their promise; NAD+ precursors are covered in hallmark 07.

7. References